Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

Department of Urology

University of Iowa Carver College of Medicine and The Holden Comprehensive Cancer Center

375 Newton Road

3210 MERF

USA

Name/email consistency: high

Department of Urology, University of Iowa Carver College of Medicine and The Holden Comprehensive Cancer Center, 375 Newton Road, 3210 MERF, USA. 2012
Department of Urology, University of Iowa, Iowa City, Iowa 52242, USA. 2006 - 2009
Department of Urology and Roland and Ruby Holden Cancer Research Laboratories, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, USA. 2006

Prostate cancer vaccines in clinical trials. Lubaroff, D.M. Expert. Rev. Vaccines (2012) [Pubmed]
Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Lubaroff, D.M., Konety, B.R., Link, B., Gerstbrein, J., Madsen, T., Shannon, M., Howard, J., Paisley, J., Boeglin, D., Ratliff, T.L., Williams, R.D. Clin. Cancer Res. (2009) [Pubmed]
CpG oligonucleotide as an adjuvant for the treatment of prostate cancer. Lubaroff, D.M., Karan, D. Adv. Drug Deliv. Rev. (2009) [Pubmed]
Clinical protocol: phase I study of an adenovirus/prostate-specific antigen vaccine in men with metastatic prostate cancer. Lubaroff, D.M., Konety, B., Link, B.K., Ratliff, T.L., Madsen, T., Shannon, M., Ecklund, D., Williams, R.D. Hum. Gene Ther. (2006) [Pubmed]
Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer. Lubaroff, D.M., Karan, D., Andrews, M.P., Acosta, A., Abouassaly, C., Sharma, M., Krieg, A.M. Vaccine (2006) [Pubmed]